Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands
- 247 Downloads
Recently, prostate-specific membrane antigen-radioguided surgery (PSMA-RGS) has been introduced as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). In the following, we want to review our experience with PSMA-RGS in patients with localised biochemical recurrent PC.
A non-systematic review of the literature was carried out with focus on technical and logistical aspects of PSMA-RGS. Furthermore, published data on intraoperative detection of metastatic lesions compared to preoperative PSMA-PET and postoperative histopathology, postoperative complications as well as oncological follow-up data are summarized. Finally, relevant aspects on prerequisites for PSMA-RGS, patient selection, and the potential benefit of additional salvage radiotherapy or potential future applications of robotic PSMA-RGS with drop-in γ-probes are discussed.
First results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for patient selection and localisation of tumour recurrence is a positive Ga-HBED-CC PSMA positron-emission tomography (PET) scan with preferably only singular soft tissue or lymph node recurrence after primary treatment. Furthermore, PSMA-RGS has the potential to positively influence oncological outcome.
PSMA-RGS seems to be of high value in patients with localised PC recurrence for exact localisation and resection of oftentimes small metastatic lesions using intraoperative and ex vivo γ-probe measurements. However, patient identification on the basis of Ga-HBED-CC-PSMA PET imaging as well as clinical parameters is crucial to obtain satisfactory results.
KeywordsSalvage surgery Oligometastatic Prostate cancer PSA PSMA Radioguided surgery
I Rauscher: Protocol/project development, Data collection and management, Data analysis, Manuscript writing and editing. T Horn: Data collection and management, Data analysis, Manuscript writing and editing. M Eiber: Protocol/project development, Data analysis, Manuscript writing and editing. JE Gschwend: Protocol/project development, Manuscript writing and editing. T Maurer: Protocol/project development, Data collection and management, Data analysis, Manuscript writing and editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest or competing interests.
Research involving human participants
All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed written consent was obtained from all individual participants included in this study.
- 6.Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q et al (2015) Prospective comparison of 18F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56(8):1185–1190PubMedCrossRefGoogle Scholar
- 12.Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70(6):926–937PubMedCrossRefGoogle Scholar
- 22.Rausch I, Bergmann H, Geist B, Schaffarich M, Hirtl A, Hacker M et al (2014) Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines. A national survey of PET/CT operations in Austria. Nuklearmedizin 53(6):242–248PubMedCrossRefGoogle Scholar
- 24.Rauscher I, Duwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K et al (2017) Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 120(1):40–47PubMedCrossRefGoogle Scholar
- 25.Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L et al (2011) Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 60(5):935–943PubMedCrossRefGoogle Scholar
- 26.Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309PubMedCrossRefGoogle Scholar